Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 238

1.

Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma.

Dimopoulos MA, Dytfeld D, Grosicki S, Moreau P, Takezako N, Hori M, Leleu X, LeBlanc R, Suzuki K, Raab MS, Richardson PG, Popa McKiver M, Jou YM, Shelat SG, Robbins M, Rafferty B, San-Miguel J.

N Engl J Med. 2018 Nov 8;379(19):1811-1822. doi: 10.1056/NEJMoa1805762.

PMID:
30403938
2.

Carfilzomib Weekly 20/56mg/m2 , Lenalidomide and Dexamethasone for Early Relapsed Refractory Multiple Myeloma.

Richez V, Gruchet C, Guidez S, Fouquet G, Azais I, Durand G, Javaugue V, Brigaud A, Plasse F, Diolez J, Machet A, Moya N, Gardeney H, Franques P, Bobin A, Levy A, Sabirou F, Bonnin A, Dieval C, Primault S, Barrier J, Fleck E, Bouyier S, Daras C, Princet I, Bauwens D, Legros L, Fuzibet JG, Gil A, Bridoux F, Avet-Loiseau H, Leleu X.

Am J Hematol. 2018 Oct 25. doi: 10.1002/ajh.25327. [Epub ahead of print] No abstract available.

PMID:
30358902
3.

Myeloma MRD by deep sequencing from circulating tumor DNA does not correlate with results obtained in the bone marrow.

Mazzotti C, Buisson L, Maheo S, Perrot A, Chretien ML, Leleu X, Hulin C, Manier S, Hébraud B, Roussel M, Do Souto L, Attal M, Avet-Loiseau H, Corre J.

Blood Adv. 2018 Nov 13;2(21):2811-2813. doi: 10.1182/bloodadvances.2018025197. No abstract available.

4.

Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma.

Leleu X, Martin TG, Einsele H, Lyons RM, Durie BGM, Iskander KS, Ailawadhi S.

Clin Lymphoma Myeloma Leuk. 2018 Sep 5. pii: S2152-2650(18)30612-8. doi: 10.1016/j.clml.2018.08.016. [Epub ahead of print] Review.

PMID:
30287200
5.

Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma.

Garderet L, Kuhnowski F, Berge B, Roussel M, Escoffre-Barbe M, Lafon I, Facon T, Leleu X, Karlin L, Perrot A, Moreau P, Marit G, Stoppa AM, Royer B, Chaleteix C, Tiab M, Araujo C, Lenain P, Macro M, Voog E, Benboubker L, Allangba O, Jourdan E, Orcsini-Piocelle F, Brechignac S, Eveillard JR, Belhadj K, Wetterwald M, Pegourie B, Jaccard A, Eisenmann JC, Glaisner S, Mohty M, Hulin C, Avet Loiseau H, Mathiot C, Attal M.

Blood. 2018 Oct 3. pii: blood-2018-07-863829. doi: 10.1182/blood-2018-07-863829. [Epub ahead of print]

PMID:
30282798
6.

Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma.

Perrot A, Lauwers-Cances V, Corre J, Robillard N, Hulin C, Chretien ML, Dejoie T, Maheo S, Stoppa AM, Pegourie B, Karlin L, Garderet L, Arnulf B, Doyen C, Meuleman N, Royer B, Eveillard JR, Benboubker L, Dib M, Decaux O, Jaccard A, Belhadj K, Brechignac S, Kolb B, Fohrer C, Mohty M, Macro M, Richardson PG, Carlton V, Moorhead M, Willis T, Faham M, Anderson KC, Harousseau JL, Leleu X, Facon T, Moreau P, Attal M, Avet-Loiseau H, Munshi N.

Blood. 2018 Sep 24. pii: blood-2018-06-858613. doi: 10.1182/blood-2018-06-858613. [Epub ahead of print]

PMID:
30249784
7.

Working Toward a Genomic Prognostic Classification of Waldenström Macroglobulinemia: C-X-C Chemokine Receptor Type 4 Mutation and Beyond.

Magierowicz M, Tomowiak C, Leleu X, Poulain S.

Hematol Oncol Clin North Am. 2018 Oct;32(5):753-763. doi: 10.1016/j.hoc.2018.05.007. Epub 2018 Jul 27. Review.

PMID:
30190015
8.

The clinical implication of monoclonal gammopathies: monoclonal gammopathy of undetermined significance and monoclonal gammopathy of renal significance.

Batko K, Malyszko J, Jurczyszyn A, Vesole DH, Gertz MA, Leleu X, Suska A, Krzanowski M, Sulowicz W, Malyszko JS, Krzanowska K.

Nephrol Dial Transplant. 2018 Aug 28. doi: 10.1093/ndt/gfy259. [Epub ahead of print]

PMID:
30169860
9.

Maintenance Treatment and Survival in Patients With Myeloma: A Systematic Review and Network Meta-analysis.

Gay F, Jackson G, Rosiñol L, Holstein SA, Moreau P, Spada S, Davies F, Lahuerta JJ, Leleu X, Bringhen S, Evangelista A, Hulin C, Panzani U, Cairns DA, Di Raimondo F, Macro M, Liberati AM, Pawlyn C, Offidani M, Spencer A, Hájek R, Terpos E, Morgan GJ, Bladé J, Sonneveld P, San-Miguel J, McCarthy PL, Ludwig H, Boccadoro M, Mateos MV, Attal M.

JAMA Oncol. 2018 Oct 1;4(10):1389-1397. doi: 10.1001/jamaoncol.2018.2961.

PMID:
30098165
10.

Interim PET Analysis in First-Line Therapy of Multiple Myeloma: Prognostic Value of ΔSUVmax in the FDG-Avid Patients of the IMAJEM Study.

Bailly C, Carlier T, Jamet B, Eugene T, Touzeau C, Attal M, Hulin C, Facon T, Leleu X, Perrot A, Garderet L, Macro M, Caillot D, Moreau P, Kraeber-Bodéré F, Bodet-Milin C.

Clin Cancer Res. 2018 Nov 1;24(21):5219-5224. doi: 10.1158/1078-0432.CCR-18-0741. Epub 2018 Aug 1.

PMID:
30068709
11.

Treatment and outcome patterns in European patients with Waldenström's macroglobulinaemia: a large, observational, retrospective chart review.

Buske C, Sadullah S, Kastritis E, Tedeschi A, García-Sanz R, Bolkun L, Leleu X, Willenbacher W, Hájek R, Minnema MC, Cheng M, Bilotti E, Graef T, Dimopoulos MA; European Consortium for Waldenström's Macroglobulinemia.

Lancet Haematol. 2018 Jul;5(7):e299-e309. doi: 10.1016/S2352-3026(18)30087-5. Review.

PMID:
29958569
12.

Phase I dose-escalation study of F50067, a humanized anti-CXCR4 monoclonal antibody alone and in combination with lenalidomide and low-dose dexamethasone, in relapsed or refractory multiple myeloma.

Fouquet G, Guidez S, Richez V, Stoppa AM, Le Tourneau C, Macro M, Gruchet C, Bobin A, Moya N, Syshenko T, Sabirou F, Levy A, Franques P, Gardeney H, Karlin L, Benboubker L, Ouali M, Vedovato JC, Ferre P, Pavlyuk M, Attal M, Facon T, Leleu X.

Oncotarget. 2018 May 8;9(35):23890-23899. doi: 10.18632/oncotarget.25156. eCollection 2018 May 8.

13.

Propensity score matching analysis to evaluate the comparative effectiveness of daratumumab versus real-world standard of care therapies for patients with heavily pretreated and refractory multiple myeloma.

Kumar S, Durie B, Nahi H, Vij R, Dimopoulos MA, Kastritis E, Terpos E, Leleu X, Beksac M, Goldschmidt H, Hillengass J, Su Z, Hutton B, Cameron C, Khan I, Lam A.

Leuk Lymphoma. 2018 May 9:1-9. doi: 10.1080/10428194.2018.1459609. [Epub ahead of print]

PMID:
29741423
14.

Patient-reported health-related quality of life from the phase III TOURMALINE-MM1 study of ixazomib-lenalidomide-dexamethasone versus placebo-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma.

Leleu X, Masszi T, Bahlis NJ, Viterbo L, Baker B, Gimsing P, Maisnar V, Samoilova O, Rosiñol L, Langer C, Song K, Izumi T, Cleeland C, Berg D, Lin HM, Zhu Y, Skacel T, Moreau P, Richardson PG.

Am J Hematol. 2018 May 4. doi: 10.1002/ajh.25134. [Epub ahead of print]

PMID:
29726031
15.

Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network.

Ludwig H, Delforge M, Facon T, Einsele H, Gay F, Moreau P, Avet-Loiseau H, Boccadoro M, Hajek R, Mohty M, Cavo M, Dimopoulos MA, San-Miguel JF, Terpos E, Zweegman S, Garderet L, Mateos MV, Cook G, Leleu X, Goldschmidt H, Jackson G, Kaiser M, Weisel K, van de Donk NWCJ, Waage A, Beksac M, Mellqvist UH, Engelhardt M, Caers J, Driessen C, Bladé J, Sonneveld P.

Leukemia. 2018 Jul;32(7):1542-1560. doi: 10.1038/s41375-018-0040-1. Epub 2018 May 2. Review.

16.

Carfilzomib in relapsed or refractory multiple myeloma patients with early or late relapse following prior therapy: A subgroup analysis of the randomized phase 3 ASPIRE and ENDEAVOR trials.

Mateos MV, Goldschmidt H, San-Miguel J, Mikhael J, DeCosta L, Zhou L, Obreja M, Blaedel J, Szabo Z, Leleu X.

Hematol Oncol. 2018 Apr;36(2):463-470. doi: 10.1002/hon.2499. Epub 2018 Feb 15.

PMID:
29446103
17.

Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a study from the Chronic Malignancies Working Party of the EBMT.

Gagelmann N, Eikema DJ, Iacobelli S, Koster L, Nahi H, Stoppa AM, Masszi T, Caillot D, Lenhoff S, Udvardy M, Crawley C, Arcese W, Mariette C, Hunter A, Leleu X, Schipperus M, Delforge M, Pioltelli P, Snowden JA, Itälä-Remes M, Musso M, van Biezen A, Garderet L, Kröger N.

Haematologica. 2018 May;103(5):890-897. doi: 10.3324/haematol.2017.178434. Epub 2018 Feb 1.

18.

Outcome of a Salvage Third Autologous Stem Cell Transplantation in Multiple Myeloma.

Garderet L, Iacobelli S, Koster L, Goldschmidt H, Johansson JE, Bourhis JH, Krejci M, Leleu X, Potter M, Blaise D, Koenecke C, Peschel C, Radocha J, Metzner B, Lenain P, Schäfer-Eckart K, Pohlreich D, Grasso M, Caillot D, Einsele H, Ladetto M, Schönland S, Kröger N.

Biol Blood Marrow Transplant. 2018 Jul;24(7):1372-1378. doi: 10.1016/j.bbmt.2018.01.035. Epub 2018 Feb 3.

PMID:
29408334
19.

Role of IRF4 in resistance to immunomodulatory (IMid) compounds® in Waldenström's macroglobulinemia.

Bertrand E, Jouy N, Manier S, Fouquet G, Guidez S, Boyle E, Noel S, Tomowiak C, Herbaux C, Schraen S, Preudhomme C, Quesnel B, Poulain S, Leleu X.

Oncotarget. 2017 Dec 4;8(68):112917-112927. doi: 10.18632/oncotarget.22872. eCollection 2017 Dec 22.

20.

Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel.

Caers J, Paiva B, Zamagni E, Leleu X, Bladé J, Kristinsson SY, Touzeau C, Abildgaard N, Terpos E, Heusschen R, Ocio E, Delforge M, Sezer O, Beksac M, Ludwig H, Merlini G, Moreau P, Zweegman S, Engelhardt M, Rosiñol L.

J Hematol Oncol. 2018 Jan 16;11(1):10. doi: 10.1186/s13045-017-0549-1. Review.

21.

Salvage therapy post pomalidomide-based regimen in relapsed/refractory myeloma.

Fouquet G, Karlin L, Macro M, Caillot D, Roussel M, Arnulf B, Pegourie B, Petillon MO, Mathiot C, Hulin C, Kolb B, Stoppa AM, Brechiniac S, Rodon P, Dib M, Tiab M, Richez V, Araujo C, Wetterwald M, Garderet L, Royer B, Perrot A, Benboubker L, Decaux O, Escoffre-Barbe M, Fermand JP, Moreau P, Avet-Loiseau H, Attal M, Facon T, Leleu X.

Ann Hematol. 2018 May;97(5):831-837. doi: 10.1007/s00277-018-3236-6. Epub 2018 Jan 12.

PMID:
29330561
22.

Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients.

Jurczyszyn A, Radocha J, Davila J, Fiala MA, Gozzetti A, Grząśko N, Robak P, Hus I, Waszczuk-Gajda A, Guzicka-Kazimierczak R, Atilla E, Mele G, Sawicki W, Jayabalan DS, Charliński G, Szabo AG, Hajek R, Delforge M, Kopacz A, Fantl D, Waage A, Avivi I, Rodzaj M, Leleu X, Richez V, Knopińska-Posłuszny W, Masternak A, Yee AJ, Barchnicka A, Druzd-Sitek A, Guerrero-Garcia T, Liu J, Vesole DH, Castillo JJ.

Br J Haematol. 2018 Mar;180(6):831-839. doi: 10.1111/bjh.15092. Epub 2018 Jan 7.

PMID:
29315478
23.

Incidence of neutropenia and use of granulocyte colony-stimulating factors in multiple myeloma: is current clinical practice adequate?

Leleu X, Gay F, Flament A, Allcott K, Delforge M.

Ann Hematol. 2018 Mar;97(3):387-400. doi: 10.1007/s00277-017-3191-7. Epub 2017 Dec 27. Review.

24.

Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond.

Chim CS, Kumar SK, Orlowski RZ, Cook G, Richardson PG, Gertz MA, Giralt S, Mateos MV, Leleu X, Anderson KC.

Leukemia. 2018 Feb;32(2):252-262. doi: 10.1038/leu.2017.329. Epub 2017 Nov 16. Review.

25.

Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the european myeloma network.

Ludwig H, Delforge M, Facon T, Einsele H, Gay F, Moreau P, Avet-Loiseau H, Boccadoro M, Hajek R, Mohty M, Cavo M, Dimopoulos MA, San-Miguel JF, Terpos E, Zweegman S, Garderet L, Mateos MV, Cook G, Leleu X, Goldschmidt H, Jackson G, Kaiser M, Weisel K, van de Donk NWCJ, Waage A, Beksac M, Mellqvist UH, Engelhardt M, Caers J, Driessen C, Sonneveld P.

Leukemia. 2017 Dec 18. doi: 10.1038/leu.2017.353. [Epub ahead of print] Review.

26.

[Circulating exosomal microRNA as biomarkers in mutiple myeloma].

Manier S, Leleu X, Avet-Loiseau H.

Med Sci (Paris). 2017 Nov;33(11):939-941. doi: 10.1051/medsci/20173311008. Epub 2017 Dec 4. French. No abstract available.

PMID:
29200389
27.

Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma.

Facon T, Dimopoulos MA, Dispenzieri A, Catalano JV, Belch A, Cavo M, Pinto A, Weisel K, Ludwig H, Bahlis NJ, Banos A, Tiab M, Delforge M, Cavenagh JD, Geraldes C, Lee JJ, Chen C, Oriol A, De La Rubia J, White D, Binder D, Lu J, Anderson KC, Moreau P, Attal M, Perrot A, Arnulf B, Qiu L, Roussel M, Boyle E, Manier S, Mohty M, Avet-Loiseau H, Leleu X, Ervin-Haynes A, Chen G, Houck V, Benboubker L, Hulin C.

Blood. 2018 Jan 18;131(3):301-310. doi: 10.1182/blood-2017-07-795047. Epub 2017 Nov 17.

28.

Our experience of solitary plasmacytoma of the bone: improved PFS with a short-course treatment by IMiDs or proteasome inhibitors combined with intensity-modulated radiotherapy.

Le Ray E, Belin L, Plancher C, Anract P, Babinet A, Dumaine V, Tamburini J, Deau Fischer B, Willems L, Magro L, Facon T, Leleu X, Bouscary D, Kirova YM.

Leuk Lymphoma. 2018 Jul;59(7):1756-1758. doi: 10.1080/10428194.2017.1393667. Epub 2017 Oct 31. No abstract available.

PMID:
29087212
29.

Sustained molecular response in chronic myeloid leukemia deep responders treated with low dose tyrosine kinase inhibitors.

Cayssials E, Tartarin F, Guilhot J, Sorel N, Chomel JC, Leleu X, Guilhot F.

Leuk Lymphoma. 2018 Mar;59(3):766-769. doi: 10.1080/10428194.2017.1357178. Epub 2017 Aug 9. No abstract available.

PMID:
28792265
30.

TP53 Mutation and Its Prognostic Significance in Waldenstrom's Macroglobulinemia.

Poulain S, Roumier C, Bertrand E, Renneville A, Caillault-Venet A, Doye E, Geffroy S, Sebda S, Nibourel O, Nudel M, Herbaux C, Renaud L, Tomowiak C, Guidez S, Tricot S, Roche-Lestienne C, Quesnel B, Preudhomme C, Leleu X.

Clin Cancer Res. 2017 Oct 15;23(20):6325-6335. doi: 10.1158/1078-0432.CCR-17-0007. Epub 2017 Jul 28.

31.

Heavy + light chain analysis to assign myeloma response is analogous to the IMWG response criteria.

Fouquet G, Snell KI, Guidez S, Schraen S, Boyle E, Renaud L, Desmier D, Machet A, Moya N, Systchenko T, Gruchet C, Decaux O, Arnulf B, Fohrer C, Richez V, Kolb B, Macro M, Karlin L, Royer B, Pegourie B, Hebraud B, Caillot D, Perrot A, Moreau P, Facon T, Avet-Loiseau H, Dejoie T, Hulin C, Harding S, Leleu X.

Leuk Lymphoma. 2018 Mar;59(3):583-589. doi: 10.1080/10428194.2017.1339876. Epub 2017 Jul 12.

PMID:
28697637
32.

Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study.

Kumar SK, Dimopoulos MA, Kastritis E, Terpos E, Nahi H, Goldschmidt H, Hillengass J, Leleu X, Beksac M, Alsina M, Oriol A, Cavo M, Ocio EM, Mateos MV, O'Donnell EK, Vij R, Lokhorst HM, van de Donk NWCJ, Min C, Mark T, Turesson I, Hansson M, Ludwig H, Jagannath S, Delforge M, Kyriakou C, Hari P, Mellqvist U, Usmani SZ, Dytfeld D, Badros AZ, Moreau P, Kim K, Otero PR, Lee JH, Shustik C, Waller D, Chng WJ, Ozaki S, Lee JJ, de la Rubia J, Eom HS, Rosinol L, Lahuerta JJ, Sureda A, Kim JS, Durie BGM.

Leukemia. 2017 Nov;31(11):2443-2448. doi: 10.1038/leu.2017.138. Epub 2017 May 12.

PMID:
28620163
33.

Leptin receptor antagonism of iNKT cell function: a novel strategy to combat multiple myeloma.

Favreau M, Menu E, Gaublomme D, Vanderkerken K, Faict S, Maes K, De Bruyne E, Govindarajan S, Drennan M, Van Calenbergh S, Leleu X, Zabeau L, Tavernier J, Venken K, Elewaut D.

Leukemia. 2017 Dec;31(12):2678-2685. doi: 10.1038/leu.2017.146. Epub 2017 May 11.

PMID:
28490813
34.

Inhibiting the oncogenic translation program is an effective therapeutic strategy in multiple myeloma.

Manier S, Huynh D, Shen YJ, Zhou J, Yusufzai T, Salem KZ, Ebright RY, Shi J, Park J, Glavey SV, Devine WG, Liu CJ, Leleu X, Quesnel B, Roche-Lestienne C, Snyder JK, Brown LE, Gray N, Bradner J, Whitesell L, Porco JA Jr, Ghobrial IM.

Sci Transl Med. 2017 May 10;9(389). pii: eaal2668. doi: 10.1126/scitranslmed.aal2668.

35.

Age-related health care disparities in multiple myeloma.

Puyade M, Defossez G, Guilhot F, Leleu X, Ingrand P.

Hematol Oncol. 2018 Feb;36(1):224-231. doi: 10.1002/hon.2422. Epub 2017 Apr 21.

PMID:
28429426
36.

A phase II Bayesian sequential clinical trial in advanced Waldenström macroglobulinemia patients treated with bortezomib: interest of addition of dexamethasone.

Leblond V, Morel P, Dilhuidy MS, Leleu X, Soussain C, Leprête S, Dreyfus B, Dartigeas C, Mahé B, Anglaret B, Pégourié B, Besson C, Aurran T, Vekhoff A, Tournilhac O, Banos A, Oya H, Lejeune J, Ouzegdouh M, Chevret S; French Innovative Leukemia Organization (FILO).

Leuk Lymphoma. 2017 Nov;58(11):2615-2623. doi: 10.1080/10428194.2017.1307357. Epub 2017 Apr 10.

PMID:
28395585
37.

Both mucosal-associated invariant and natural killer T-cell deficiency in multiple myeloma can be countered by PD-1 inhibition.

Favreau M, Venken K, Faict S, Maes K, De Veirman K, De Bruyne E, Leleu X, Boon L, Elewaut D, Vanderkerken K, Menu E.

Haematologica. 2017 Jul;102(7):e266-e270. doi: 10.3324/haematol.2017.163758. Epub 2017 Apr 6. No abstract available.

38.

Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.

Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M, Arnulf B, Macro M, Belhadj K, Garderet L, Roussel M, Payen C, Mathiot C, Fermand JP, Meuleman N, Rollet S, Maglio ME, Zeytoonjian AA, Weller EA, Munshi N, Anderson KC, Richardson PG, Facon T, Avet-Loiseau H, Harousseau JL, Moreau P; IFM 2009 Study.

N Engl J Med. 2017 Apr 6;376(14):1311-1320. doi: 10.1056/NEJMoa1611750.

39.

Analysis of a Compartmental Model of Endogenous Immunoglobulin G Metabolism with Application to Multiple Myeloma.

Kendrick F, Evans ND, Arnulf B, Avet-Loiseau H, Decaux O, Dejoie T, Fouquet G, Guidez S, Harel S, Hebraud B, Javaugue V, Richez V, Schraen S, Touzeau C, Moreau P, Leleu X, Harding S, Chappell MJ.

Front Physiol. 2017 Mar 17;8:149. doi: 10.3389/fphys.2017.00149. eCollection 2017.

40.

Prospective longitudinal study on quality of life in relapsed/refractory multiple myeloma patients receiving second- or third-line lenalidomide or bortezomib treatment.

Leleu X, Kyriakou C, Vande Broek I, Murphy P, Bacon P, Lewis P, Gilet H, Arnould B, Petrucci MT.

Blood Cancer J. 2017 Mar 17;7(3):e543. doi: 10.1038/bcj.2017.20.

41.

Prognostic role of circulating exosomal miRNAs in multiple myeloma.

Manier S, Liu CJ, Avet-Loiseau H, Park J, Shi J, Campigotto F, Salem KZ, Huynh D, Glavey SV, Rivotto B, Sacco A, Roccaro AM, Bouyssou J, Minvielle S, Moreau P, Facon T, Leleu X, Weller E, Trippa L, Ghobrial IM.

Blood. 2017 Apr 27;129(17):2429-2436. doi: 10.1182/blood-2016-09-742296. Epub 2017 Feb 17.

42.

Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib-dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study.

Ludwig H, Weisel K, Petrucci MT, Leleu X, Cafro AM, Garderet L, Leitgeb C, Foa R, Greil R, Yakoub-Agha I, Zboralski D, Vauléon S, Dümmler T, Beyer D, Kruschinski A, Riecke K, Baumann M, Engelhardt M.

Leukemia. 2017 Apr;31(4):997-1000. doi: 10.1038/leu.2017.5. Epub 2017 Jan 11. No abstract available.

43.

BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 years.

Gavriatopoulou M, García-Sanz R, Kastritis E, Morel P, Kyrtsonis MC, Michalis E, Kartasis Z, Leleu X, Palladini G, Tedeschi A, Gika D, Merlini G, Sonneveld P, Dimopoulos MA.

Blood. 2017 Jan 26;129(4):456-459. doi: 10.1182/blood-2016-09-742411. Epub 2016 Nov 21.

44.

The LIN28B/let-7 axis is a novel therapeutic pathway in multiple myeloma.

Manier S, Powers JT, Sacco A, Glavey SV, Huynh D, Reagan MR, Salem KZ, Moschetta M, Shi J, Mishima Y, Roche-Lestienne C, Leleu X, Roccaro AM, Daley GQ, Ghobrial IM.

Leukemia. 2017 Apr;31(4):853-860. doi: 10.1038/leu.2016.296. Epub 2016 Oct 24.

45.

Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma.

Dejoie T, Corre J, Caillon H, Hulin C, Perrot A, Caillot D, Boyle E, Chretien ML, Fontan J, Belhadj K, Brechignac S, Decaux O, Voillat L, Rodon P, Fitoussi O, Araujo C, Benboubker L, Fontan C, Tiab M, Godmer P, Luycx O, Allangba O, Pignon JM, Fuzibet JG, Legros L, Stoppa AM, Dib M, Pegourie B, Orsini-Piocelle F, Karlin L, Arnulf B, Roussel M, Garderet L, Mohty M, Meuleman N, Doyen C, Lenain P, Macro M, Leleu X, Facon T, Moreau P, Attal M, Avet-Loiseau H.

Blood. 2016 Dec 22;128(25):2941-2948. doi: 10.1182/blood-2016-07-726778. Epub 2016 Oct 11.

46.

Treatment of Newly Diagnosed Elderly Multiple Myeloma.

Fouquet G, Gay F, Boyle E, Bringhen S, Larocca A, Facon T, Leleu X, Palumbo A.

Cancer Treat Res. 2016;169:123-143. Review.

PMID:
27696261
47.

A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS).

Hájek R, Masszi T, Petrucci MT, Palumbo A, Rosiñol L, Nagler A, Yong KL, Oriol A, Minarik J, Pour L, Dimopoulos MA, Maisnar V, Rossi D, Kasparu H, Van Droogenbroeck J, Yehuda DB, Hardan I, Jenner M, Calbecka M, Dávid M, de la Rubia J, Drach J, Gasztonyi Z, Górnik S, Leleu X, Munder M, Offidani M, Zojer N, Rajangam K, Chang YL, San-Miguel JF, Ludwig H.

Leukemia. 2017 Jan;31(1):107-114. doi: 10.1038/leu.2016.176. Epub 2016 Jun 24.

48.

Recommendations for the diagnosis and initial evaluation of patients with Waldenström Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenström Macroglobulinaemia.

Castillo JJ, Garcia-Sanz R, Hatjiharissi E, Kyle RA, Leleu X, McMaster M, Merlini G, Minnema MC, Morra E, Owen RG, Poulain S, Stone MJ, Tam C, Varettoni M, Dimopoulos MA, Treon SP, Kastritis E.

Br J Haematol. 2016 Oct;175(1):77-86. doi: 10.1111/bjh.14196. Epub 2016 Jul 5.

49.

Usual risk factors do not predict venous thromboembolism in newly diagnosed myeloma treated with immunomodulatory drugs.

Chalayer E, Chapelle C, Leleu X, Elalamy I, Laporte S, Tardy B.

Am J Hematol. 2016 Oct;91(10):E455-6. doi: 10.1002/ajh.24454. Epub 2016 Jul 14. No abstract available.

50.

Updated Outcomes and Impact of Age With Lenalidomide and Low-Dose Dexamethasone or Melphalan, Prednisone, and Thalidomide in the Randomized, Phase III FIRST Trial.

Hulin C, Belch A, Shustik C, Petrucci MT, Dührsen U, Lu J, Song K, Rodon P, Pégourié B, Garderet L, Hunter H, Azais I, Eek R, Gisslinger H, Macro M, Dakhil S, Goncalves C, LeBlanc R, Romeril K, Royer B, Doyen C, Leleu X, Offner F, Leupin N, Houck V, Chen G, Ervin-Haynes A, Dimopoulos MA, Facon T.

J Clin Oncol. 2016 Oct 20;34(30):3609-3617. doi: 10.1200/JCO.2016.66.7295.

PMID:
27325857

Supplemental Content

Support Center